The inflammation-based modified Glasgow Prognostic Score in patients with vulvar cancer.

Abstract Objectives To evaluate the prognostic potential of the modified Glasgow Prognostic Score (mGPS), known to reflect the degree of tumor-associated inflammation and cachexia, in patients with vulvar cancer. Study design We included 93 consecutive patients with vulvar cancer into our study. As previously published, the pre-therapeutic mGPS was calculated as follows: patients with elevated C-reactive protein (CRP) serum levels (>10 mg/L) and hypoalbuminaemia ( Results Mean (SD) pretreatment CRP and albumin serum levels were 9.5 (9.6) mg/L and 41.4 (5.3) g/L, respectively. mGPS was associated with tumor stage ( p  = 0.01), but not with lymph node involvement ( p  = 0.4), histological grade ( p  = 0.8), and patients’ age ( p  = 0.7). In univariate analyses, mGPS ( p  = 0.006, p  = 0.001), tumor stage ( p p p p p  = 0.04, p  = 0.007), but not histological grade ( p  = 0.1, p  = 0.3) and year of surgery (1995–2001 vs. 2002–2008, p  = 0.7, p  = 0.3) were associated with disease-free and overall survival, respectively. In a multivariate analysis, tumor stage ( p  = 0.01, p  = 0.02) and lymph node involvement ( p p  = 0.001), but not mGPS ( p  = 0.7, p  = 0.8), patients’ age ( p  = 0.6, p  = 0.4), histological grade ( p  = 0.2, p  = 0.1), and year of surgery ( p  = 0.4, p  = 0.8) were associated with disease-free and overall survival, respectively. Conclusions Despite being associated with prognosis in a univariate analysis, mGPS cannot be used as an independent inflammation-based predictor for survival in patients with vulvar cancer.